TIDMPRTC
RNS Number : 6703T
PureTech Health PLC
18 November 2019
18 November 2019
PureTech Health plc
PureTech Affiliate Karuna Therapeutics Announces KarXT Met
Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in
Patients with Schizophrenia
KarXT Demonstrated Statistically Significant and Clinically
Meaningful Improvement in Total PANSS Score at All Time Points Over
Five Weeks and was Well-Tolerated Compared to Placebo
Improvement in Total PANSS Score at Five Weeks was 11.6 Points
Compared to Placebo (p<0.0001)
No Evidence of Somnolence, Extrapyramidal Side Effects or Weight
Gain Relative to Placebo
Data Support Advancing KarXT to Phase 3 and Continued
Development in Other CNS Disorders
Karuna Management to Host Conference Call and Webcast Today at
8:30 a.m. EST / 1:30 p.m. GMT
PureTech Health plc (LSE: PRTC) ("PureTech"), a clinical stage
biotechnology company dedicated to discovering, developing and
commercialising highly differentiated medicines for devastating
diseases, is pleased to note that Karuna Therapeutics, Inc.
(Karuna), an affiliate of PureTech, today announced results from
its Phase 2 clinical trial of KarXT for the treatment of acute
psychosis in patients with schizophrenia. In the clinical trial,
KarXT demonstrated a statistically significant and clinically
meaningful 11.6 point mean reduction in total Positive and Negative
Syndrome Scale (PANSS) score compared to placebo (p<0.0001) and
also demonstrated good overall tolerability. A statistically
significant reduction in the secondary endpoints of PANSS-Positive
and PANSS-Negative scores were also observed (p<0.001).
The magnitude of the improvement with KarXT compares favorably
to meta-analyses of published clinicals trials of currently
approved antipsychotic medicines which reported an average
difference of nine to ten points in PANSS score versus placebo.
Historically, changes as small as five points have supported the
approval of current antipsychotics.
KarXT was well tolerated in the Phase 2 trial, with similar
discontinuation rates between KarXT (20%) and placebo (21%). The
number of discontinuations due to treatment emergent adverse events
(AEs) were equal in the KarXT and placebo arms (N=2 in each
group).
Daphne Zohar, founder and chief executive officer of PureTech
said: "These impressive results are another important validation of
PureTech's innovation engine that has generated highly
differentiated platforms to address serious diseases, leading to 24
product candidates, including 14 clinical stage and one recently
FDA cleared product. It is very exciting to see Karuna reach this
important milestone with its lead candidate KarXT that originated
at PureTech. KarXT is now being advanced by one of the leading CNS
drug development teams and has the potential to be the first novel
therapeutic approach in decades to treat psychosis in patients with
schizophrenia and Alzheimer's disease."
Conference Call and Webcast Information
Karuna will hold a webcast and conference call this morning at
8:30 a.m. EST / 1:30 p.m. GMT to provide results from its Phase 2
clinical trial of KarXT for the treatment of acute psychosis in
patients with schizophrenia. The dial-in numbers are 1-855-548-1216
for domestic callers and 1-409-216-6318 for international callers.
The conference ID number for the live call will be 9498519. A live
webcast of the conference call will also be available on the
investor relations page of the Karuna Therapeutics corporate
website at www.karunatx.com. After the live webcast, the event will
remain archived on the Karuna Therapeutics website for three
months.
The full text of the announcement from Karuna Therapeutics is as
follows:
Karuna Therapeutics Announces KarXT Met Primary Endpoint in
Phase 2 Clinical Trial of Acute Psychosis in Patients with
Schizophrenia
KarXT Demonstrated Statistically Significant and Clinically
Meaningful Improvement in Total PANSS Score at All Time Points Over
Five Weeks and was Well-Tolerated Compared to Placebo
Improvement in Total PANSS Score at Five Weeks was 11.6 Points
Compared to Placebo (p<0.0001)
No Evidence of Somnolence, Extrapyramidal Side Effects or Weight
Gain Relative to Placebo
Data Support Advancing KarXT to Phase 3 and Continued
Development in Other CNS Disorders
Conference Call and Webcast to Take Place Today at 8:30 a.m.
EST
BOSTON-Nov. 18, 2019-Karuna Therapeutics, Inc. (Nasdaq: KRTX), a
clinical-stage biopharmaceutical company committed to developing
novel therapies with the potential to transform the lives of people
with disabling and potentially fatal neuropsychiatric disorders and
pain, today announced results from its Phase 2 clinical trial of
KarXT for the treatment of acute psychosis in patients with
schizophrenia. In the clinical trial, KarXT demonstrated a
statistically significant and clinically meaningful 11.6 point mean
reduction in total Positive and Negative Syndrome Scale (PANSS)
score compared to placebo (p<0.0001) and also demonstrated good
overall tolerability. A statistically significant reduction in the
secondary endpoints of PANSS-Positive and PANSS-Negative scores
were also observed (p<0.001).
KarXT was well tolerated in the Phase 2 trial, with similar
discontinuation rates between KarXT (20%) and placebo (21%). The
number of discontinuations due to treatment emergent adverse events
(AEs) were equal in the KarXT and placebo arms (N=2 in each
group).
KarXT is an oral coformulation of xanomeline (a novel muscarinic
receptor agonist) and trospium (a muscarinic receptor antagonist)
designed to treat psychosis and related symptoms through
preferential stimulation of muscarinic receptors in the central
nervous system (CNS). This combination has the potential to be a
new option for treating the difficult symptoms of debilitating CNS
disorders, such as schizophrenia, without subjecting patients to
the problematic side effects associated with current antipsychotic
standard of care therapies.
"The results of the Phase 2 trial are impressive and encouraging
because they indicate that KarXT, if approved, could represent a
game-changing therapeutic advance in the treatment of patients with
schizophrenia," said Jeffrey Lieberman, M.D., professor and
chairman of the Department of Psychiatry, Columbia University,
College of Physicians and Surgeons and a member of Karuna's
scientific advisory board. "The effectiveness of antipsychotics has
been limited by the frequent and serious side effects of first- and
second-generation drugs which are difficult for many patients to
tolerate, are potentially harmful, and lead to high rates of
discontinuation and relapse. In addition to its novel mechanism of
action, KarXT could be a new therapeutic option that has the
potential to offer robust efficacy devoid of weight gain, metabolic
effects and extrapyramidal side effects."
In the clinical trial, patients demonstrated a clinically
meaningful and statistically significant 11.6 point mean reduction
over placebo in total PANSS score, the trial's primary efficacy
endpoint. The magnitude of the improvement with KarXT compares
favorably to meta-analyses of published clinicals trials of
currently approved antipsychotic medicines which reported an
average difference of nine to ten points in PANSS score versus
placebo. Historically, changes as small as five points have
supported the approval of current antipsychotics.
Overall, KarXT was well tolerated in the clinical trial, with
similar discontinuation rates of patients on KarXT, 20%, and
placebo, 21%. The number of discontinuations due to treatment
emergent AEs were equal in the KarXT and placebo arms (N=2 in each
group). The overall AE rate of patients on KarXT was 54% vs. 43% on
placebo, with the most common AEs being constipation, nausea, dry
mouth, dyspepsia, and vomiting. The tolerability of KarXT was also
reflected in the trial's high rate of dose escalation. In the
trial, 91% of KarXT treated patients escalated to the increased
dose which was similar to the escalation rate with placebo.
Occurrences of somnolence, weight gain, and extrapyramidal symptoms
were also similar to placebo. One serious adverse event (SAE) was
experienced in the drug treatment arm, in which the patient
discontinued treatment and subsequently sought hospital care for
worsening psychosis, meeting the regulatory definition of an
SAE.
"The schizophrenia treatment landscape has remained rather
stagnant for decades with therapeutic options relying on
discoveries dating back to the 1950s," said Steve Paul, M.D., chief
executive officer, president, and chairman of Karuna. "KarXT and
its novel muscarinic receptor mechanism of action represent the
potential to become a true advancement in how schizophrenia is
treated, allowing patients relief from their debilitating psychotic
symptoms without experiencing some of the very troubling side
effects associated with current treatments."
Muscarinic acetylcholine receptors emerged in the 1990s as a
promising alternative target to dopamine-receptor based treatments
for treating psychosis, but adverse side effects limited their
development as a therapeutic option. It is believed that these side
effects were the result of the stimulation of muscarinic receptors
in peripheral tissues. Karuna addressed this issue by combining
xanomeline, a novel muscarinic receptor agonist that preferentially
stimulates M1 and M4 muscarinic receptors, with trospium, an
approved muscarinic receptor antagonist that does not measurably
cross the blood-brain barrier, confining its effects to peripheral
tissues. The resulting therapeutic, known as KarXT, was designed to
activate muscarinic receptors in the CNS while avoiding the side
effects associated with activating muscarinic receptors in
peripheral tissues.
"We are extremely pleased with these results, as the 11.6-point
PANSS score separation from placebo far exceeded the five-point
minimum improvement that has historically supported approval of
current antipsychotics," said Stephen Brannan, M.D., chief medical
officer of Karuna. "With this information, and following our
anticipated end-of-Phase 2 meeting with the FDA in the second
quarter of 2020, we will work to initiate a Phase 3 clinical trial
of KarXT in patients with schizophrenia by the end of 2020. We also
plan to further analyze these results to better understand the
potential of KarXT in patients with schizophrenia experiencing
negative and cognitive symptoms, and to explore other CNS disorders
that could benefit from this approach, such as psychosis in
Alzheimer's disease as well as the management of pain."
About the Trial
The Phase 2, randomized, double-blind, placebo-controlled,
inpatient trial enrolled 182 adult patients, age 18 to 60, who had
been diagnosed with DSM-5 schizophrenia and were experiencing acute
psychosis. Patients were washed-out of antipsychotic medicines and
randomized 1:1 to receive either KarXT or placebo for five weeks.
The primary outcome measure of the trial was the change from
baseline on the total PANSS score on KarXT vs. placebo treatment at
week five.
KarXT was dosed as xanomeline 50 mg/trospium 20 mg twice a day
for two days and then increased to xanomeline 100 mg/trospium 20 mg
starting on day three. Beginning on day eight, if KarXT was well
tolerated, an option was given to escalate the dose of KarXT to
xanomeline 125 mg/trospium 30 mg twice a day. If a patient
escalated to the highest dose, the dose could be decreased back to
xanomeline 100 mg/trospium 20 mg twice per day, based on
tolerability, if needed. No dose changes were allowed during the
last two weeks of the trial.
About Schizophrenia
Schizophrenia is a chronic, disabling disorder typically
diagnosed in late teenage years or early adulthood. Characterized
by recurring episodes of psychosis requiring long-term treatment
with antipsychotic drugs in most patients, it affects more than 21
million people worldwide and 2.7 million Americans (0.5% - 1.0% of
U.S. population).
At least one-third of patients with schizophrenia fail to
respond to current treatments, with 74% of patients discontinuing
within 18 months of initiation. People with schizophrenia have a
10- to 15-year reduction in life expectancy and struggle to
maintain meaningful interpersonal relationships. The World Health
Organization ranks psychosis as the third-most disabling medical
condition in the world.
Conference Call and Webcast Information
Karuna will hold a webcast and conference call this morning at
8:30 a.m. EST to provide results from its Phase 2 clinical trial of
KarXT for the treatment of acute psychosis in patients with
schizophrenia. The dial-in numbers are 1-855-548-1216 for domestic
callers and 1-409-216-6318 for international callers. The
conference ID number for the live call will be 9498519. A live
webcast of the conference call will also be available on the
investor relations page of the Karuna Therapeutics corporate
website at www.karunatx.com. After the live webcast, the event will
remain archived on the Karuna Therapeutics website for three
months.
About Karuna
Karuna is a clinical-stage biopharmaceutical company committed
to developing and delivering first-in-class therapies with the
potential to transform the lives of people with CNS disorders -
which remain among the most disabling and potentially fatal
disorders worldwide. Galvanized by the understanding that today's
neuropsychiatric and pain management patients deserve better,
Karuna's mission is to harness the untapped potential of the
brain's complex biology in pursuit of novel therapeutic pathways
that will advance the standard of care. For more information,
please visit karunatx.com.
About PureTech Health
PureTech is a clinical stage biotechnology company dedicated to
discovering, developing and commercialising highly differentiated
medicines for devastating diseases, including intractable cancers,
lymphatic and gastrointestinal diseases, central nervous system
disorders, and inflammatory and immunological diseases, among
others. The Company has created a broad and deep pipeline through
the expertise of its experienced research and development team and
its extensive network of scientists, clinicians and industry
leaders. This pipeline, which is being advanced both internally and
through PureTech's affiliates, is comprised of 24 product
candidates and one product that has been cleared by the US Food and
Drug Administration (FDA). All of the underlying programmes and
platforms that resulted in this pipeline of product candidates were
initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company's
unique insights into the biology of the brain, immune, and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGGGQPGUPBUWR
(END) Dow Jones Newswires
November 18, 2019 06:03 ET (11:03 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024